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Abstract
There has been accumulating evidence for the involvement of retroviral integrase (IN) in the reverse transcription of viral
RNA. We previously identified a host factor, survival motor neuron-interacting protein 1 (SIP1/Gemin2) that binds to human
immunodeficiency virus type 1 (HIV-1) IN and supports HIV-1 infection apparently at reverse transcription step. Here, we
demonstrated that HIV-1 IN together with SIP1 augments reverse transcriptase (RT) activity by enhancing the assembly of
RT on viral RNA in vitro. Synthetic peptides corresponding to the binding motifs within IN that inhibited the IN-SIP1
interaction abrogated reverse transcription in vitro and in vivo. Furthermore, knockdown of SIP1 reduced intracellular
stability and multimer formation of IN through proteasome-mediated degradation machinery. Taken together, SIP1 appears
to stabilize functional multimer forms of IN, thereby promoting the assembly of IN and RT on viral RNA to allow efficient
reverse transcription, which is a prerequisite for efficient HIV-1 infection.
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Introduction
Upon infection of host cells with a retrovirus, the viral genome is
subjected to several processes that include uncoating, reverse
transcription of the viral genomic RNA into a cDNA copy by
reverse transcriptase (RT), transport of this cDNA into the
nucleus, and integration of the cDNA into the host chromosome.
These early events are mediated through the interactions of several
viral proteins and host factors with the viral genome, often referred
as reverse transcription complex (RTC) or preintegration complex
(PIC) [1,2]. The cDNA copy of the viral genome integrates into a
host cell chromosome by integrase (IN) [3]. Several cellular
proteins have been reported to interact directly with HIV-1 IN,
including integrase interactor 1 [4], lens epithelium-derived
growth factor/transcription co-activator p75 (LEDGF/p75) [5]
for chromosomal targeting of HIV-1 IN [6–8]. More recently, von
Hippel-Lindau binding protein 1 (VBP1), a subunit of the
prefoldin chaperone, has been identified as an IN cellular binding
protein that bridges interaction between IN and the cullin2 (Cul2)-
based von Hippel-Lindau (VHL) ubiquitin ligase [9]. VBP1 and
the Cul2/VHL ligase cooperate in the efficient polyubiquitylation
of IN and its subsequent proteasome-mediated degradation that is
perquisite for efficient transcription from integrated viral DNA.
Putative roles for IN at steps prior to integration, such as
uncoating [10–12], reverse transcription [11,13–15], and nuclear
import of viral cDNA [14,16,17] have been suggested. Although
the mechanisms for these pleiotropic effects of IN mutations are
largely unknown, there has been accumulating evidence for the
involvement of retroviral INs in the reverse transcription
[11,13,14,18,19]. Contribution of IN during the reverse transcrip-
tion has also been noticed in a retrovirus like element of
Saccharomyces cerevisiae, Ty3 [20,21]. A previous study from our
laboratory showed that reverse transcription of HIV-1 was
abrogated by knocking down a host factor, survival motor neuron
(SMN)-interacting protein 1 (SIP1/Gemin2) that binds to HIV-1
IN [22]. SIP1/Gemin 2 is a component of the SMN complex that
mediates the assembly of spliceosomal small nuclear ribonucleo-
proteins (snRNPs) and nucleolar ribonucleoproteins (snoRNP)
[23–27].
In the present study, we identified critical residues within IN for
interaction with SIP1. Interruption of the IN-SIP1 interaction
through introducing the mutations in HIV-1 IN or with synthetic
peptides corresponding to the binding motif of the IN for SIP1
resulted in abrogation of reverse transcription, indicating that IN-
SIP1 interaction is a prerequisite for efficient HIV-1 infection. For
mechanistic insight of the SIP1-IN interaction, we demonstrate that
HIV-1 IN and SIP1 synergistically stimulate RT activity by
enhancing the assembly of RT on viral RNA in vitro. Furthermore,
we also showed that SIP1 stabilizes the formation of a functional
multimer of IN, thereby promoting the assembly of IN and RT on
viral RNA to allow an efficient reverse transcription. Our findings
will shed light on the mechanism of the functional role of IN during
reverse transcription of the retroviral genome and could serve as a
basis for a novel therapeutic approach to treat HIV-1 disease.
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Intracellular Interaction between HIV-1 IN and SIP1
Previous studies showed that mutations in the conserved amino
acid residues of HIV-1 IN abolished reverse transcription of viral
genomic RNA after infection [11,12,14,18]. Firstly, we examined
theeffectoftheseINmutations includingY15A [28],K186Q,Delta
KRK[14],andLL241,242AA[18]ontheirintracellularinteraction
with endogenous SIP1 (Figure 1A). For this assay, an IN protein
with the V5 epitope at its COOH-terminus was expressed in 293T
cells, then subjected to immunoprecipitation with an anti-V5
antibody followed by Western blotting using an anti-SIP1 antibody.
A specific interaction of the wild type IN-V5 (WT-V5) with SIP1
was detected (Figure 1B). When variants of IN-V5 carrying each
mutation were expressed in 293T cells, levels of the Y15A-V5,
K186Q-V5 and LL241,242AA-V5 IN variants were significantly
lower than that of WT (Figure S1A). Therefore, the amount of
mutant plasmid vector used was increased to result in steady-state
levels of the IN-V5 variant proteins similar to that of the WT-V5
control. Under these experimental conditions, all of the IN carrying
mutation of Y15A, K186Q, Delta-KRK or LL241,242AA
significantly reduced binding to endogenous SIP1 (Figure 1B).
Interestingly,wenoticedthat deletionoftheKRK186–188residues
(Delta-KRK) increased the steady-state level of IN significantly
(Figure S1A) and that introduction of the Delta-KRK mutation in
Y15A mutant (Y15A-delKRK) restored the stability (Figure S1B).
These results suggest that the KRK residues might be critical for
proteasome-mediated degradation that accompanied with loss of
SIP1 interaction as shown in the following experiments. In parallel,
IN-V5 carrying a D116G mutation at the IN catalytic sites was also
tested, since HIV-1 with a D116G variant of IN is defective for
proviral integration but retains normal level of cDNA synthesis
(reverse transcription) activity [11,29,30]. D116G-V5 interacted
with endogenous SIP1 as efficiently as WT-V5. Thus, all of the IN
mutations that cause reverse transcription defective phenotype, at
least tested here, significantly reduced the intracellular interaction
with SIP1, suggesting that the interaction of IN with SIP1 is critical
for efficient reverse transcription in the HIV-1 infection cycle. Next,
to map the domain(s) of IN that are essential for interaction with
SIP1, a series of truncated forms of IN were examined. Consistent
with our previous pull-down study using recombinant GST-IN
fusion protein [22], the COOH-terminal domain of IN (IN-Cter,
201–288) and full-length IN (IN1–288) each bound to SIP1
efficiently (Figure 1C). The NH2-terminal domain of IN (IN1–55)
andthecentralcoredomainofIN(IN51–212)showedmuchweaker
affinity compared to the C-terminal domain (IN201–288). Of note,
the addition of the central core domain to the C-terminal domain
(IN51–288) significantly enhanced binding with SIP1. These results
suggest that both the central core and the C-terminal domains of
HIV-1 IN contribute to efficient binding to SIP1 within cells.
Direct Interaction between Recombinant IN and SIP1
Proteins In Vitro
We then evaluated the direct interaction between HIV-1 IN and
SIP1 by using recombinant IN and SIP1 proteins in vitro.
Recombinant His-tagged IN protein with full size (His-WT) or a
series of deletions (Figure 2A) was incubated with recombinant SIP1
(rSIP1). The reaction mixture was then subjected to nickel-column
purification followed by Western blotting using an anti-SIP1
antibody. The His-WT and His-1–270 variant in which the 18
amino acids from the C-terminal of IN were deleted showed efficient
interaction with rSIP1 in vitro. Further deletions of the C-terminus
(His-1–260, -1–250, and -1–240) significantly reduced binding to
rSIP1. This finding suggests that the residues between 240 to 260
within the C-terminal domain of IN are critical for the direct
interaction with SIP1. Curiously, further deletion of residues from
the C-terminus of His-IN (His-1–230, 1–220) significantly restored
binding of IN to rSIP1 (Figure 2B), suggesting that there is an
additional binding motif outside of the C-terminal domain of HIV-1
IN. It is also plausible that in the absence of the C-terminal residues,
the residues 240–260 may be inhibitory to the binding motif outside
of the C-terminal domain of HIV-1 IN. However, as demonstrated
inthefollowingexperiments,thepeptidecorrespondingtotheregion
(IN231–251) inhibit the IN-SIP1 interaction and its RT-stimulatory
effects, indicating contribution of the residues of 240–260 for
functionallyrelevantbindingtoSIP1atleastinthefulllengthformof
HIV-1 IN. On the other hand, residues of 1–60 (His-1–60) or 1–70
(His-1–70) did not bind to rSIP1, while residues of His-1–80, -1–90,
and -1–100 exhibited significant binding to rSIP1 (Figure 2C). Thus,
residues of 71–80 in the central core domain of HIV-1 IN are also
critical for the interaction with SIP1.
Further mutational analyses targeting the residues of 71–80
revealed that Val75 and Ala76 were critical for the interaction of
the IN1–90 form with rSIP1 (Figure 2D). However, in the context
of full-length form of IN, mutations of the Val75-Al76 residues
(VA75,76AG) did not affect the binding of full-length IN to rSIP1.
Similarly, none of the Y15A, K186Q, or LL241,242AA mutations
that affected the intracellular interaction of HIV-1 IN and SIP1
(Figure 1B) affected the interaction in vitro (Figure S2). However,
the full-length IN protein carrying both of the VA75,76AG and
Figure 1. Intracellular interaction between SIP1 and IN mutants
resulting in a reverse transcription defective phenotype. (A)
Schematic diagram of HIV-1 integrase. Numbers refer to amino-acid
residues of IN. The locations of the critical amino acids for reverse
transcription in vivo (Tyr15, Lys 186, Arg187 and Lys188, and
LeuLeu241,242) and the active site residues Asp116 are indicated. The
region of each truncated form of IN is shown as a solid line. (B, C) Wild
type (WT) or IN mutant expression plasmids with a V5-tag were
transfected into 293T cells. For transfection, 1.0 mg of each plasmid for
WT-V5, D116G, N-ter, Cen, C-ter, N-Cen or Cen-C, and 2.5 mg for Y15A,
K186Q, delta-KRK or LL241,242AA was used, respectively. At 48 h after
transfection, cells were harvested and lysed with RSB-100 containing
1.0% NP-40. Cell lysate was then subjected to immunoprecipitation
using an anti-V5 antibody, followed by Western blot analysis with an
anti-SIP1 antibody. H and L denote heavy and light chains of
immunoglobulin, respectively.
doi:10.1371/journal.pone.0007825.g001
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to rSIP1 in vitro (Figure 2E). These results show that the Val75-
Ala76 and Leu241-L242 residues of HIV-1 IN are critical for
direct binding with SIP1. The apparent discrepancy between the
in vivo and in vitro binding assays could be due to different folding of
the protein under the two different conditions, suggesting that the
Y15A, K186Q, or LL241–242AA mutations might affect the
conformation or the higher-order structure of HIV-1 IN that is
required for efficient interaction with SIP1 in vivo. It is also possible
that additional motifs including the residues of Y15, K186 and
LL241–242 and/or factor(s) might be involved for the IN-SIP1
interaction in vivo.
Characterization of Intracellular IN Proteins in SIP1 Knock-
Down Cells
Several groups have reported that IN is subject to degradation
by the cellular ubiquitin-proteasome system [9,31]. Thus, we
examined whether SIP1 might act to protect HIV-1 IN from
proteasomal degradation. In 293T cells, expression levels of
mutants Y15A-V5, K186Q-V5 and LL241,242AA-V5 were lower
than those of WT-V5 (Figure S1). Of note, treatment with the
proteasome inhibitor MG132 restored the expression levels of the
IN mutants (Figure 3A), suggesting that these mutants might be
susceptible to proteasome-mediated degradation. We tested this
hypothesis by using RNAi to specifically knockdown SIP1 in cells.
The siRNA against SIP1 (siSIP1) significantly reduced the level of
IN-V5 (Figure 3B). Under the same conditions, siSIP1 did not
affect the level of LacZ-V5, an unrelated control protein. Of note,
the level of IN-V5 in siSIP1-treated cells was restored by addition
of MG132 (Figure 3C), suggesting that SIP1 might contribute to
intracellular IN stability by protecting it from proteasome-
mediated protein degradation. Interestingly, the expression level
of the Delta-KRK-V5 mutant was high in both the presence and
absence of MG132 treatment (Figure S1 and Figure 3A). Thus, the
Delta-KRK mutation might affect the susceptibility of IN to
ubiquitination, or other steps required for proteasome-mediated
protein degradation. On the other hand, knocking down SIP1 did
not affect the overall intracellular localization of IN-V5 (Figure
S3). Importantly, the level of WT-V5 was not changed by
treatment with MG132, suggesting that WT-V5 can form stable
conformations that protect it from proteasome-mediated protein
degradation through an interaction with SIP1 (Figure 3A). Of
note, the Y15A and K186Q mutations were localized predomi-
Figure 2. Residues of HIV-1 IN that are critical for specific
interactions with recombinant SIP1 in vitro. (A) A schematic of the
full length (open bar, top) of HIV-1 IN and its deletion forms (solid line)
are shown. Point mutations of the residues of IN (Val75, Ala76, Leu241
and Leu242) that are critical for interaction with SIP1, are indicated with
their location numbers. (B, C) For pull-down experiments, 10 mgo f
recombinant SIP1 was incubated with 10 mg of each His-tagged IN (His-
IN), followed by purification through a nickel agarose column. The level
of SIP1 bound to each IN-nickel agarose complex was determined by
Western blot analysis using an anti-SIP1 antibody. (D) Series of amino
acid substitutions targeting the residues from 71 to 80 of the His-
tagged IN (1–90) protein were generated. Interaction of each mutant
protein with SIP1 was determined as described above in (B). (E) Full-
length His-tagged IN mutant proteins carrying the VA74,75AG or
LL241,242AA mutations were generated. Interaction of each mutant
protein with SIP1 was determined as described above in (B).
doi:10.1371/journal.pone.0007825.g002
Figure 3. Characterization of intracellular IN proteins. (A) 293T
cells were transfected with indicated plasmid in presence of 10 mM MG-
132 (+) or DMSO(2). Total cell lysates (10 mg) were analyzed by Western
blotting analysis. (B, C) 293T cells were transfected twice with 100 pmol
of siControl or siSIP1 and then with lacZ-V5 or an IN-V5 expression
plasmid with MG-132 or DMSO. 48 h later, cells were lysed with CSK
buffer containing 0.5% NP-40 followed by Western blotting analysis. (D,
E) 293T cells transfected each IN-V5 expression vector were suspended
with CSK buffer containing 0.5% NP-40. Cell lysates were incubated in
either the absence or presence of 0.2 mM DTSSP at room temperature
for 20 min and analyzed by Western blotting using an anti-V5 antibody.
(F) Cell lysates in (B) were treated with 0.2 mM of DTSSP and then
analyzed by Western blotting. The relative ratio of monomers, dimers,
and tetramers after treatment with 0.2 mM DTSSP was analyzed using
Image-J software (bottom). The relative ratio (%) of each form to the
total level of IN-V5 is indicated.
doi:10.1371/journal.pone.0007825.g003
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expression compared with WT-IN (Figure S1). Therefore, we
hypothesize that SIP1 might exert its effect in the cytoplasm to
stabilize functional IN conformations that are required for efficient
viral cDNA synthesis.
It has been reported that HIV-1 IN functions as a dimer or
other higher-order structure [32–35]. Cross-linking experiments
using 3,39-Dithiobis sulfosuccinimidylpropionate (DTSSP) re-
vealed that the IN dimer, trimer or tetramer forms could be
easily detected when wild type IN-V5 was expressed in 293T cells
(Figure 3D). Meanwhile, Y15A-V5, K186Q-V5, or LL241–
242AA IN mutants produced very low levels of the dimer or
multimer forms under the same experimental conditions. Inter-
estingly, the Delta-KRK mutant was detected as a dimer, but to a
lesser extent as a tetramer. High molecular weight bands for the
Y15A-V5, K186Q-V5, or LL241–242AA IN mutants were
evident when the cross-linking experiment was performed in the
presence of MG132 (Figure 3E). Since high molecular weight
bands for the WT-V5 and Delta-KRK mutants were less evident
in the presence of MG132, the high molecular weight bands might
represent aggregated forms of IN proteins resulting from improper
multimerization, which would be subject to proteasome-mediated
degradation. These results suggest that proper multimerization,
most probably in a tetramer formation of IN, might be required
for efficient interaction with SIP1. Importantly, in SIP1 knock-
down cells, IN-V5 dimer formation was still observed, although
the total level of IN-V5 was reduced (Figure 3F, top). Of note,
tetramer formation of IN-V5 was reduced to about 50% of the
level in control siRNA treated cells (Figure 3F, bottom). Thus,
SIP1 might contribute to the formation and/or stability of higher-
ordered forms of HIV-1 IN, thereby protecting IN from
proteasome-mediated protein degradation machinery.
Augmentation of Reverse Transcription by HIV-1 IN and
SIP1 In Vitro
Recently, Chow and colleagues have reported that HIV-1 IN
plays an important role during the reverse-transcription step of the
viral life cycle through physical interactions with RT [36].
Moreover, they have indicated that IN augments the initiation
and elongation steps of HIV-1 reverse transcription in vitro [19].
We examined the functional role of HIV-1 IN and SIP1 during
the reverse transcription of viral RNA using an in vitro cell-free RT
assay. In this RT assay, in vitro transcribed RNA with a 59m
7 G
Cap analog and 39poly (A) tail, mimicking the HIV-1 genomic
RNA in a virus particle, was used as a template RNA. For a
primer, synthetic ribonucleotides that were designed to be
annealed with the primer binding site (PBS) of HIV-1 were used.
The amount of recombinant RT (35 fmoles per reaction) and the
template RNA (0.04,0.4 fmoles/reaction) was optimized to
detect IN-mediated augmentation of RT activity. The level of
the cDNA products (R/U5) was significantly increased by WT-IN
at the dose of 35 (P=0.02) and 350 fmoles per reaction (P=0.03).
Truncated form of HIV-1 IN (IN1–70) that lacks the central and
C-terminal domains containing SIP1 binding regions, however,
exhibited no significant stimulatory effect at any dose
(P=0.58,0.98) (Figure 4A). Importantly, stimulation of RT
activity by IN was further enhanced by SIP1 in a dose-dependent
manner (Figure 4C). Significant stimulation of RT activity by SIP1
(P=0.001) was evident when the full-length IN (IN-WT) was
present (Figure 4D). However, SIP1 alone, nor with IN1–70
exhibited no significant (P=0.69 and 0.98, respectively) stimula-
tory effect (Figure 4D and Figure S4A). The effect of SIP1 was not
evident when higher amounts of the IN protein were added to the
RT assay (Figure S4B), suggesting that SIP1 functions in IN-
dependent manner. Thus, SIP1 might be required for the efficient
recruitment of IN into the reverse transcription complex in the
natural course of viral infection where the amounts of IN and RT
are limiting.
To examine the sizes of the cDNA products in our RT assay, we
carried out the in vitro RT assay with [a
32P] dCTP and subjected
to PAGE analysis. We obtained smear bands ranging from 50 to
180 nt, the amount of which was augmented by the IN and SIP1
(Figure S4C). Thus, most of the cDNA products in our RT assay
might be the early species of cDNA including the minus strand
strong-stop cDNA, expected size of which is ,170 nt. Meanwhile,
the level of the late cDNA products (R/gag) was always less than
1% of the total cDNA (R/U5) level at any dose of IN (Figure 4B).
The R/gag cDNA products were detected even without PBS
primer if high amount of RNA or RNA without heat-denature
were used (data not shown). Therefore, most of the R/gag cDNA
products might be synthesized by self-priming through an inter- or
intra-hybridization of RNA templates by themselves. Of note, IN
and SIP1 decreased the level of the R/gag products compared to
IN1–70 control, suggesting that IN and SIP1 might increase the
correct initiation of cDNA synthesis from the PBS primer. Taken
Figure 4. Augmentation of reverse transcription by HIV-1 IN
and SIP1 in vitro. (A, B) The in vitro RT assay was carried out with
35 fmoles of HIV-1 RT (GST-RTp66) in the absence or presence of
different amounts of full-length rIN (WT-IN). The truncated form of IN
(IN1–70) that lack SIP1 binding domains was also tested in apparel as a
control. The amount of HIV-1 cDNA was measured by real-time PCR
using the HIV-1 R/U5 (A) or R/gag (B) primer pair [11]. Significant
augmentation (p,0.05) by WT-IN in the levels of HIV-1 cDNA compared
with the level without IN (0 fmole) was indicated by asterisks. (C) The in
vitro RT assay was carried out as described in (A) in either the absence
or presence of 3.5 moles of WT-IN, together with different amounts of
rSIP1. (D) The in vitro RT assay was carried out with 3.5 fmoles of WT-IN
(black bar) or IN1–70 (slash bar), in either the absence (2) or presence
(+) of 50 fmoles of rSIP1. (E) The oligo(dT) cellulose resin was incubated
with in vitro transcribed HIV-1 RNA for 1 h. After incubation, 10 mgo f
GST-RT in either the absence or presence of His-IN or rSIP1 was added
and incubated for 2 h. After four washes with the IN storage buffer,
precipitates were analyzed by immunoblot analysis using an anti-GST
antibody.
doi:10.1371/journal.pone.0007825.g004
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and elongation of viral cDNA during the strong-stop cDNA
synthesis.
Next, the effects of IN and SIP1 on the assembly of RT on viral
RNA was examined. Briefly, in vitro transcribed HIV-1 RNA
immobilized on oligo-d(T) cellulose resin was incubated with
recombinant RT in either the presence or absence of IN and SIP1.
Levels of RT on viral RNA were determined by immunoblot
assay. In the presence of IN, the level of RT on viral RNA was
increased in a dose-dependent manner. SIP1, together with IN,
enhanced RT assembly on viral RNA (Figure 4E). Thus, HIV-1
IN stimulates RT activity together with SIP1 by enhancing or
stabilizing RT assembly on viral RNA.
Interruption of the SIP1-IN Interaction with Synthetic
Peptides Corresponding to the Binding Motif of IN for
SIP1
Binding assays revealed that residues in the central and the C-
terminal domains of HIV-1 IN are critical for efficient binding to
SIP1 (Figure 2). Synthetic peptides corresponding to the residues
of 60–80 (IN60–80) and the residues of 231–251(IN 231–251) of
HIV-1 IN were generated (Figure 5A). The direct binding of each
peptide to SIP1 was evaluated using the dot-blot binding assay as
described elsewhere [37]. Peptides corresponding to the residues
of 154–174 (IN154–174), which contain a motif critical for the
interaction with LEDGF/p75 [38,39], were used as a control.
Both peptides, IN60–80 and IN 231–251, efficiently bound to
rSIP1 under conditions in whichthe controlpeptide, IN154–174,
did not (Figure 5B). Furthermore, both of the IN60–80 and
IN231–251 peptides significantly interfered with the binding of
the full-length IN (His-WT) to the SIP1 protein. About 5 mMo f
the IN60–80 peptide reduced His-WT binding to SIP1 to non-
specific background levels, whereas at least 50 mM of the IN231–
251 peptide was required to produce a similar effect (Figure 5C).
Thus, the inhibitory effect of IN60–80 was more than 10 times
higher than that of IN231–251. Of note, the IN60–80 peptide
and the IN232–251 peptide significantly reduced the IN-SIP1
mediated RT activity in a dose-dependent manner, while the
inhibitory effect was not evident with the control IN154–174
peptide (Figure 5D). The inhibitory effect of IN60–80
(IC50=,10 pmoles per reaction) was more than 100 times
higher than that of IN231–251 (IC50=,1 nmoles per reaction).
Interestingly, we also found that synergic inhibitory effect of the
IN231–251 with IN60–80 (Figure S5). Thus, although the
inhibitory effect of the IN231–251 was much lower than that
by the IN60–80 but significant wh e nc o m p a r e dw i t ht h ec o n t r o l
peptide, suggesting contribution of the regions corresponding to
the IN231–251, in addition to IN60–80, for efficient binding with
SIP1.
Finally, the effect of each peptide on HIV-1 replication was also
examined. For this experiment, we used monocyte cell line, THP-1
that was treated with PMA to differentiate to macrophage-like cells
to facilitate uptake of the peptide through phagocytosis. Compared
to the control peptide IN154–174 or the DMSO control, the IN60–
80 peptide significantly reduced HIV-1 infectivity to 20–25% of
control (Figure 5E). IN231–251 did not significantly reduce HIV-1
infectivity under these conditions. Furthermore, peptide IN60–80
reduced viral cDNA synthesis to less than 25% of control
(Figure 5F). Thus, these data demonstrate that the interaction of
HIV-1 IN with SIP1 is critical for efficient reverse transcription of
viral RNA after HIV-1 infection. We tested the effect of this peptide
on Moloney murine leukemia virus (MMLV) using MMLV-based
retroviral vector system (pFB-Luc retroviral vector, Stratagene).
MMLV cannot establish in non-dividing cells such as THP-1 cells
treated with PMA in which effect of the peptide was evident for
HIV-1cDNA synthesis.Nonetheless,we found that cDNA synthesis
was efficiently occurred in these PMA-treated THP-1 cells after
infection of MMLV-based VSVG pseudotype vector (Figure S6).
Therefore, we examined for effectof the peptides on MMLV cDNA
synthesis after infection. We found no significant inhibitory effect of
the IN60–80 peptide on MLV cDNA synthesis compared with
DMSO or control peptide, ruling out the non-specific inhibitory
effects of the IN60–80 during virus binding and entry into the cells.
Discussion
Contribution of IN during the reverse transcription has been
reported not only in HIV-1 [10–12,14,18,36] but also in a
retrovirus like element of Saccharomyces cerevisiae, Ty3 [20,21].
Figure 5. IN-derived peptide inhibits reverse transcription in
vitro and in vivo. (A) Amino acid sequences of IN-derived peptides are
indicated. (B) 40 or 400 nmol of each peptide bound to nitrocellulose
filter was incubated with rSIP1 (5 mg). The rSIP1 bound to the peptide
was detected using an anti-SIP1 antibody. (C) His-IN (10 mg) was bound
to nitrocellulose and reacted with 5 mg of rSIP1 in the presence of each
peptide at the indicated concentration. The rSIP1 bound to the peptide
was detected as described in (B). (D) The in vitro reverse transcription
assay was performed with 35 fmol of RT, 3.5 fmol of His-IN, and 50 fmol
of rSIP1 in either the absence (control) or presence of IN-derived
peptide at the indicated concentration. The values (mean6SE) plotted
are the levels of HIV-1 cDNA relative to that the control, taken as 1.0. (E,
F) PMA-stimulated THP-1 cells were treated with 100 mM of IN-derived
peptide for 16 h. Cells were infected with HIVNL43-luc/VSV-G pseudo-
types [11] in the presence of 100 mM of IN-derived peptide for 6 h. At
24 h post-infection, levels of viral gene expression in cells were
determined by measuring the luciferase activity (E) and the levels of
viral cDNA synthesis for early (R/U5, black bar) and late (R/gag, slash
bar) products (F) were determined as described in Figure 4.
doi:10.1371/journal.pone.0007825.g005
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[15,36,40,41] and certain mutations of IN result in viruses
defective in early steps of reverse transcription [36,40]. Further-
more, analysis using cell-free RT assay revealed that IN enhances
both initiation and elongation modes of reverse transcription in
vitro [19]. These studies suggest that the interaction between IN
and RT is functional and critical for viral replication. In this study,
we firstly showed that the IN mutations Y15A [28], K186Q, Delta
KRK [14], and LL241,242AA [18] that cause reverse transcrip-
tion defective phenotype, significantly reduced the intracellular
interaction with SIP1 (Figure 1). Similar effect was also reproduced
in other IN mutations [11] that cause reverse transcription
defective phenotype such as C43L and P29F (data not shown).
Meanwhile, several other IN variants have been described in the
literature to be defective for viral reverse transcription. Some of
these IN mutations such as C130S [36], H12A, H16A and F185A
[15] reduced the association with RT or RTC. It would be
interesting to examine whether these other reverse transcription-
defective IN variants also exhibit poor binding to SIP1. These
results suggest that the interaction of IN with SIP1 is critical for
efficient reverse transcription in the HIV-1 infection cycle. Of
note, we confirmed the enhancement of RT activity by IN using in
vitro RT assay and the addition of SIP1 in the RT reaction
mixture further enhanced RT in the presence of IN but not
without IN (Figure 4–5). In this RT assay, we used 3.5,35 fmoles
of RT (corresponding to 0.01,0.1 units of conventional RT
activity) with 0.4,0.04 fmoles of RNA templates, since if we used
higher amount of RT and the template RNA, effect of IN became
less evident. The key factor for the IN-mediated RT stimulatory
effect is the ratio of amounts of RT and template RNA. In our in
vitro RT assay, we used the ratio of RT: RNA 1,000:1 to 100:1.
Since each mature virus particle contains about 250 molecules of
RT [42], our experimental condition might be physiologically
relevant to the natural condition during HIV-1 infection cycle.
Importantly, the stimulatory effect of SIP1 on RT could not
observed when high amount of IN protein was present (Figure
S4B). We also noticed the following points; First, SIP1 cannot bind
to RT directly. Second, IN can bind to RT directly without SIP1.
Third, RT-IN-SIP1 complex can be formed without RNA (data
not shown). These data showed that SIP1 could play a critical
function as an IN-cofactor, but may not directly interact with the
RT. Furthermore, we also found that that pre-incubation of RT
and IN before SIP1 resulted in most effective stimulatory effect
(Figure S4D). Taken together, these results suggest that IN binds to
RT first then with SIP1 to stabilize RT/IN/RNA complex during
HIV-1 infection cycle.
We also demonstrate that SIP1 stabilizes the formation of a
functional multimer of IN. In cell lines knocked down for
LEDGF/p75, which is important for nuclear/chromosomal
targeting of HIV-1 IN [7,43], steady state levels of HIV-1 IN
expression were markedly reduced [44]. Interestingly, IN-V5
protein with the Y15A or K186Q mutations were localized
predominantly in cytoplasm (data not shown) and exhibited a low
level of expression compared with WT-IN (Figure S1A).
Therefore, we hypothesize that SIP1 might exert its effect in the
cytoplasm, whereas LEDGF/p75 exerts effects in the nucleus to
stabilize functional IN conformations that are required for efficient
cDNA synthesis and establishing proviral DNA, respectively. It
would be of great interest to delineate this point.
The crystal structure of the N-terminal and catalytic core
domains (IN1–212) of HIV-1 integrase has been determined [33].
It should be noted that, in the crystal structure of HIV-1 IN1–212,
two dimers form a tetramer. In the crystal structure of the IN1–
212 tetramer, Y15 is located at the dimer-dimer interface of the
integrase tetramer and the side chain of Y15 stacks on the side
chain of K186 of other subunit. It is notable that a mutation of
K186 was also found to abrogate the infectivity [14]. NMR
analysis of an isolated N-terminal domain (IN1–55) has shown that
IN1–55 exists in two conformational states, E and D forms [45].
The two forms differ in the coordination of the zinc ion by two
histidine residues. Previously, structural analysis of a Y15A mutant
by NMR spectroscopy indicated that the mutant protein folds
correctly but takes only the E form [28]. Thus, it was suggested
that the interaction between Y15 and K186 is required for the
optimal tetramerization of integrase, which is required for efficient
interaction with SIP1 with the critical motif of IN 60–80 and IN
231–251, locates in the core and the C-terminal domain,
respectively.
Recent study using a large-scale small interfering RNA screen
identified more than 250 host factors required for HIV-1 infection
[46,47]. Interaction of these host factors and virus could be
possible targets for development of new class of HIV-1 inhibitors.
SIP1 was noticed as one of the host factors required for HIV-1
infection in the genome-wide screening analysis [46]. Thus,
targeting the IN-SIP1 interaction might provide beneficial
therapeutic results. The dimer form of SIP1 interacts with dimer
forms of SMN and enhances the SMN oligomer formation and the
assembly activity of snRNP [48]. It is unclear which form of IN
could interact with dimer form of SIP1. In our present study, we
showed that IN-Y15A was defective for multimerization and had a
poor binding ability with SIP1, and low stability in vivo. In vitro,
SIP1 are capable of interacting with recombinant IN-Y15A in
which formed the dimer, but not tetramer (data not shown). These
results suggest that similar to interaction with SMN, SIP1 may
recognize the dimer form of IN preferentially and play an
important role of the stabilization of functional high-order
structure forms of IN. In addition, IN-derived peptide (IN60–80)
corresponding to one of the IN motif essential for binding to SIP1
specifically block IN-mediated RT stimulatory effect and HIV-1
replication. The IN60–80 peptide does not directly suppress viral
entry and RT enzymatic activity (data not shown). These results
suggest the critical role of the IN-SIP1 interaction in reverse
transcription in viral replication cycle. Since SIP1 has critical
cellular functions, it is obvious that drugs should be highly specific
for the IN-SIP1 interface.
In summary, we demonstrated here that HIV-1 IN and SIP1
synergistically augment viral cDNA synthesis by enhancing the
assembly of RT on viral RNA in vitro. In addition, the disruption of
the SIP1-IN interaction with synthetic peptides confirmed the
critical role of the IN and SIP1 interaction in reverse transcription
and the HIV-1 replication cycle. These results could serve as a
basis for novel approaches in the development of HIV-1 inhibitors
that target IN and host factor interactions [49,50].
Materials and Methods
Plasmids
To create plenti-IN-V5, pNL4-3 [51] was amplified with the
sense primer and antisense primer. The resulting fragments were
cloned into pENTR using the TOPO Cloning Kits (Invitrogen),
and transferred into pLenti6/V5-DEST (Invitrogen) by LR
recombination. The human beta-globin intron sequences were
introduced in pLenti6/V5-DEST using the NdeI and EcoRI sites.
To generate the GST-tagged SIP1 bacterial expression construct
pGEX-SIP1, the SIP1 gene was amplified from pTRE-SIP1
(kindly provided by Dr. G. Dreyfuss) by PCR and cloned into
BamHI and EcoRI sites of pGEX-6P-2 (Amersham Pharmacia
Biotech). To generate pQE30-IN for the bacterial expression of
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3 and was inserted into pQE30 (QIAGEN) between BamHI and
SalI sites.
Immunoprecipitation
The plasmids encoding integrase or its mutants were transfected
into 293T cells using lipofectamine 2000 (Invitrogen). At 48 h
post-transfection, transfected cells were harvested and suspended
in 0.8 ml RSB-100 (10 mM Tris-HCl, pH 7.5, 100 mM NaCl,
and 2.5 mM MgCl2) with 1% Nonidet P-40. Cell lysates were
centrifuged at 15,0006g for 20 min at 4uC. The supernatant was
incubated with 4 mg of anti-V5 polyclonal antibody (Delta Biolabs)
and 40 ml of protein G-Sepharose 4B Fast Flow beads (Amersham
Pharmacia Biotech) for 2 h at 4uC. The beads were washed with
wash buffer A (20 mM Tris-HCl, pH 7.5, 250 mM NaCl, 1 mM
EDTA, 0.5 M LiCl 5% glycerol, 1% TritonX-100, and 0.25%
Nonidet P-40) and then with RSB-100 containing 1% Nonidet
P-40. The immunocomplex was eluted by boiling with 20 mlo f5 6
sample buffer and analyzed by SDS-PAGE and Western blot.
In Vitro Binding Assay
10 mg of His-tagged integrase or its deletion mutant was
incubated with 10 mg of SIP1 and 30 ml of Ni-NTA agarose
(QIAGEN) in storage buffer (20 mM HEPES pH 7.5, 0.1 mM
EDTA, 300 mM NaCl, 10 mM chaps, and 20% glycerol) at 4uC.
After a 2 h incubation, beads were washed with wash buffer A and
RSB-100 containing 1% Nonidet P-40, then boiled in 20 mlo f5 6
sample buffer. The samples were subjected to SDS-PAGE
followed by Western blot analysis.
Dot-Blot Binding Assay
His-tagged integrase (10 mg) or IN-derived peptides were bound
to the nitrocellulose membranes for 30 min. The blots were
incubated with blocking buffer for 16 h at 4uC. After washing with
TBS-T (20 mM Tris-HCl pH 7.4, 135 mM NaCl, and 0.05%
Tween 20), the membranes were incubated with 10 mg of SIP1 in
blocking buffer for 2 h at room temperature, followed by washing
with TBS-T. The blots were incubated with mouse anti-SIP1
antibodies for 2 h at room temperature, and then washed with
TBS-T. After the incubation was performed with horseradish
peroxidase-conjugate anti-mouse IgG antibodies for 1 h at room
temperature, blots were washed and SIP1 was detected using ECL
solution.
Cross-Linking
293T cells were lysed with CSK buffer (10 mM Pipes pH 6.8,
10% (w/v) sucrose, 1 mM dithiothreitol, 1 mM MgCl2, 400 mM
NaCl, and 0.5% Nonidet P-40) [5]. Then, cell lysates were
incubated with 3,39-Dithiobis [sulfosuccinimidylpropionate]
(DTSSP) at room temperature for 20 min. The cross-linking
reaction was terminated by the addition of 56sample buffer.
Transfection of siRNA
Control (59-CAA GGA CGU UCU AAG GUG GAG AGC U-
39) and SIP1 (59-CCU UGC UUA GUA UUG UUA GCA GAA
U-39)-specific siRNAs were purchased from Invitrogen. 293T cells
were transfected with 40 nM of siRNA using Lipofectamine 2000
(Invitrogen).
Purification of Recombinant IN and SIP1
The plasmids pGEX-SIP1, pQE30-IN encoding GST-tagged
SIP1, or His-tagged IN were transformed into E. coli BL21
(pGEX-SIP1) or M15 (pQE30-IN). To purify GST-SIP1, cells
were cultured in LB medium at 37uC for 16 h, diluted at 1:40 in
fresh LB medium containing 100 mg/ml ampicillin and incubated
at 37uC. When the cells reached a density of OD600=0.8, IPTG
was added to reach a final concentration of 1 mM. The cells were
harvested by centrifuging at 50006g, and lysed with PBS
containing 1 M NaCl, 1% TritonX-100, and 3 mM DTT. The
cell lysates were sonicated and centrifuged for 1 h at 24,0006g.
The supernatant was incubated in a glutathione Sepharose 4B
column (Amersham Pharmacia Biotech). The columns were
washed with phosphate-buffered saline (PBS) containing 1 M
NaCl and 1% TritonX-100. GST-tagged SIP1 was eluted with
2 ml of elution buffer (15 mM reduced glutathione, 1 mM EDTA,
150 mM NaCl, and 20 mM Tris-HCl, pH 7.5). Purified GST-
tagged SIP1 was cleaved from GST by PreScission protease
(Amersham Pharmacia Biotech). To prepare His-IN, lysis of
bacteria was carried out using the same procedure as described for
GST-SIP1. His-tagged IN was bound to Ni-NTA agarose, washed
with PBS containing 50 mM imidazole, 1 M NaCl, 1% TritonX-
100 and 3 mM DTT, and eluted with 500 mM imidazole
containing 1 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl,
pH 7.5 and 1% TritonX-100. Proteins were then dialyzed against
storage buffer (300 mM NaCl, 20 mM HEPES, pH 7.5, 1 mM
EDTA, 1 mM DTT, and 20% (w/v) glycerol).
In Vitro RT Assay
For preparation of the viral RNA template for in vitro
transcription, the DNA sequences corresponding to HIV-1
lentiviral genomic RNA (pCS-CDF-CG-PRE) [52] were sub-
cloned into pGEM-T vector (pGEM-CS-CDF). Then, the
annealed oligonucleotides of TCGA(A)30G and TCGA(T)30C
were inserted into the pGEM-CS-CDF vector at the Sal-I site for
addition of the poly(A) tail (the pGEM-CS-CDF-PolyA). Synthe-
sized HIV RNA with the poly(A) 30 tail were produced by in vitro
transcription using RiboMAX
TM Large Scale RNA Production
System-T7 (Promega) with Ribo m
7 G Cap analog (Promega) to
mimic the capped structure of mRNA. Transcription products of
HIV-1 RNA (4.9 kb) were purified with spin columns Micro-
Spin
TM G-25 Columns (American Biosciences), followed by gel-
filtration using NAP-5 columns, (American Biosciences) and were
used in the in vitro RT assay. The reverse transcription reactions
were carried out in a final volume of 20 ml RT reaction buffer
consisting of 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM
MgCl2, 10 mM DTT, 1 mM dNTPs, 0.04,0.4 fmoles of HIV-1
RNA templates and 0.4,4 fmoles of RNA primer, 3.5,35 fmol
HIV-1 RT (GST-RTp66). The reaction was carried out at 42uC
for 30 min in either the absence or presence of different amount of
His-IN and recombinant SIP1. The amount of the cDNA product
was measured by real-time PCR using primers for the R/U5 or
R/gag region [11].
Supporting Information
Figure S1 IN mutants showing lowered affinity with SIP1 are
unstable in 293T cells. (A) 293T cells were transfected with 1 mgo f
V5-tagged IN (WT) or its mutants or LacZ expression plasmid. At
48 after transfection, cells were suspended with 400mCSK buffer
containing 0.5% NP-40. Cell lysates were separated on SDS-
PAGE gel and analyzed by western blotting using anti-V5
antibody. (B) V5-tagged IN containing Y15A alone or Delta-
KRK and Y15A mutations was analyzed as described in (A).
Found at: doi:10.1371/journal.pone.0007825.s001 (14.18 MB
TIF)
Figure S2 Recombinant IN mutants showing RT defective
phenotype interact with recombinant SIP1 in vitro. The recombi-
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coupled to nickel agarose. The complexes were precipitated and
performed western blotting using anti-SIP1 antibody. NC
indicates that 10 mg of recombinant SIP1 was incubated with
nickel agarose in the absence of His-tagged IN.
Found at: doi:10.1371/journal.pone.0007825.s002 (6.01 MB TIF)
Figure S3 The subcellular localization of IN does not alter in
SIP1-deficient cells. At 48 h after transfection of siRNA and IN-
V5 expression plasmid, 293T cells were fractionated into
cytoplasmic, membrane, nuclear and cytoskeleton. Each fraction
was analyzed by western blotting using anti-V5 antibody, anti-
SIP1 antibody, or anti-histone H3 antibody as nuclear fraction
control.
Found at: doi:10.1371/journal.pone.0007825.s003 (6.01 MB TIF)
Figure S4 Stoichiometry and order of IN and SIP1 for their
stimulatory effect of cDNA synthesis. (A) The in vitro RT assay was
carried out in the absence or presence of different amount of the
His-IN (0.2 or 1 pmol) or recombinant SIP1 (0.2 or 1 pmol) as
described in Figure 4. The amount of cDNA product was
measured by real-time PCR using primers for HIV-1 R/U5
region. (B) The in vitro RT assay was carried out with 5 pmoles of
His-IN in the absence or presence of different amount SIP1 (1 or
5 pmol). (C) The in vitro RT assay was carried out in the absence or
presence of the His-IN and recombinant SIP1 with [a32P]dCTP
and subjected to SDS-PAGE analysis in denatured condition. (D)
In vitro RT assay was performed as described above, except that
rIN with rRT and rSIP1 were pre-incubated on ice in different
combinations and orders (inlet Table). Then, reaction was initiated
by adding mixture containing the template RNA/PBS-primer and
dNTPs.
Found at: doi:10.1371/journal.pone.0007825.s004 (0.10 MB
PDF)
Figure S5 Synergistic inhibitory effect of IN60–80 and IN231–
251. The in vitro reverse transcription assay was performed with
35 fmol of RT, 3.5 fmol of His-IN, and 50 fmol of rSIP1 in either
the absence (DMSO control) or presence of 1 nmole of each IN-
derived peptide or combinations containing 0.5 nmoles of each
peptide.
Found at: doi:10.1371/journal.pone.0007825.s005 (0.04 MB
PDF)
Figure S6 Effect of the IN-derived peptide on MLV cDNA
synthesis. PMA-stimulated THP-1 cells were treated with 100 mM
of IN-derived peptide for 16 h. Cells were infected with Moloney
murine leukemia virus (MMLV)-based retroviral vector (pFB-Luc
retroviral vector, Stratagene) in the presence of 100 mM of IN-
derived peptide for 6 h. At 24 h post-infection, the level of MLV
cDNA synthesis for early (R/U5) products of reverse transcription
in cells.
Found at: doi:10.1371/journal.pone.0007825.s006 (0.04 MB
PDF)
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